Guardian Therapeutics

Aptamers

Aptamers are short nucleic acids that fold into distinct tertiary structures in order to recognize specific target molecules
At the molecular level, aptamers bind to their target site through electrostatic and hydrophobic interactions as well as complementary shapes
High affinity (KD = pM-nM)
Aptamers have the ability to disrupt protein:protein interactions and produce therapeutic effects
Guardian’s aptamers are stable in serum (>120hr) and simulated gastric fluid (>24hrs)

BT200 aptamer:vWF A1 domain complex

Zhu et al, J Thromb Haemost. 2020 Feb 3.

Therapeutic Areas & Programs

We focus on four different therapeutic areas and programs, each with their own targets.

Hematology

Gastroenterology

Dermatology

Oncology

Revolutionizing Discovery Of Aptamer Therapeutics

Rapid Aptamer Discovery Process

Deep Sequencing

Therapeutic-relevant Nucleotide Chemistries

High-throughput Aptamer Synthesis

Zhu et al, J Thromb Haemost. 2020 Feb 3.

Our People

Meet the leaders who are innovating Aptamer Therapeutics

Our People

Meet the leaders who are innovating Aptamer Therapeutics

Contact

Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com